EZH2 and plasma cell myeloma: This is particularly promising given the lack of effective therapeutic options for these patients.4 Importantly, we identify a therapeutic index between myeloma and normal peripheral blood cells, supporting the rationale for EZH2 inhibition as a therapeutic strategy for myeloma patients.